Search results
Screening recommendations should be adapted based on anatomy, (i.e., annual, routine screening for chlamydia in cisgender women < 25 years old should be extended to all transgender men and gender diverse people with a cervix.
This 2021 Recommendation Statement from the US Preventive Services Task Force recommends that all sexually active women 24 years or younger and women 25 years or older at increased risk for infection be screened for chlamydia (B recommendation) and gonorrhea (B recommendation) and concludes that current evidence is insufficient to assess the ...
- Amy Cantor, Tracy Dana, Jessica C. Griffin, Heidi D. Nelson, Chandler Weeks, Kevin L. Winthrop, Roge...
- 2021
The US Preventive Services Task Force (USPSTF) concludes with moderate certainty that screening for chlamydia in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection has moderate net benefit.
- US Preventive Services Task Force, Karina W. Davidson, Michael J. Barry, Carol M. Mangione, Michael ...
- 2021
The Task Force recommends screening all sexually active women and pregnant people age 24 years and younger for chlamydia and gonorrhea. Screening is also recommended for women and pregnant people age 25 years and older who are at increased risk for infection. These are B recommendations.
- 554KB
- 2
- Follow-Up
- Management of Sex Partners
- Special Considerations
Test of cure to detect therapeutic failure (i.e., repeat testing 4 weeks after completing therapy) is not advised for nonpregnant persons treated with the recommended or alternative regimens, unless therapeutic adherence is in question, symptoms persist, or reinfection is suspected. Moreover, using chlamydial NAATs at <4 weeks after completion of t...
Sex partners should be referred for evaluation, testing, and presumptive treatment if they had sexual contact with the partner during the 60 days preceding the patient’s onset of symptoms or chlamydia diagnosis. Although the exposure intervals defining identification of sex partners at risk are based on limited data, the most recent sex partner sho...
Pregnancy
Clinical experience and published studies indicate that azithromycin is safe and effective during pregnancy (824–826). Doxycycline is contraindicated during the second and third trimesters of pregnancy because of risk for tooth discoloration. Human data reveal that levofloxacin presents a low risk to the fetus during pregnancy but has potential for toxicity during breastfeeding; however, data from animal studies increase concerns regarding cartilage damage to neonates (431). Test of cure (i.e...
Sep 29, 2021 · Based on its review of the available evidence, the task force recommended screening for chlamydia and gonorrhea in all sexually active women, including pregnant people, if they are 24 years...
Mar 24, 2021 · For women aged 30–65 years, the USPSTF recommends screening every 3 years with cervical cytology alone, every 5 years with high-risk human papillomavirus (hrHPV) testing alone, or every 5 years with hrHPV testing in combination with cytology (cotesting) (Grade A).
